EE201100023A - Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine - Google Patents
Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamineInfo
- Publication number
- EE201100023A EE201100023A EEP201100023A EEP201100023A EE201100023A EE 201100023 A EE201100023 A EE 201100023A EE P201100023 A EEP201100023 A EE P201100023A EE P201100023 A EEP201100023 A EE P201100023A EE 201100023 A EE201100023 A EE 201100023A
- Authority
- EE
- Estonia
- Prior art keywords
- combination
- fatty acid
- products containing
- medicinal products
- containing fatty
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title 1
- 229940045145 uridine Drugs 0.000 title 1
- -1 uridine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01110608 | 2001-04-30 | ||
| US28809001P | 2001-05-03 | 2001-05-03 | |
| EP01124879 | 2001-10-18 | ||
| US33042901P | 2001-10-22 | 2001-10-22 | |
| EEP200300536A EE05434B1 (et) | 2001-04-30 | 2002-04-29 | Farmatseutiliselt aktiivsed uridiiniestrid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE201100023A true EE201100023A (et) | 2011-08-15 |
Family
ID=32598659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP201100023A EE201100023A (et) | 2001-04-30 | 2002-04-29 | Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US7560442B2 (enExample) |
| JP (1) | JP4880190B2 (enExample) |
| EA (1) | EA200301204A1 (enExample) |
| EE (1) | EE201100023A (enExample) |
| RS (2) | RS51031B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20050158258A1 (en) * | 2004-01-21 | 2005-07-21 | Mary Kay Inc. | Methods and compositions for the treatment of skin changes associated with aging and environmental damage |
| US8084500B2 (en) * | 2005-01-14 | 2011-12-27 | Nutrition Therapeutics, Inc. | Method of using catalpic acid to treat dyslipidemia |
| US7687544B2 (en) * | 2005-01-14 | 2010-03-30 | Nutrition Therapeutics, Inc. | Method of using catalpic acid to treat type 2 diabetes and associated disorders |
| US8420122B2 (en) * | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| EP2012753A2 (en) * | 2006-04-28 | 2009-01-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| WO2009097596A1 (en) * | 2008-01-31 | 2009-08-06 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| US8329663B2 (en) * | 2008-01-31 | 2012-12-11 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| JP5669729B2 (ja) * | 2008-05-13 | 2015-02-12 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダＧｅｎｍｅｄｉｃａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓｌ | 代謝性障害を治療するのに有用なサリチレートコンジュゲート |
| US8950583B2 (en) * | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| CA2755069A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| AU2010297933A1 (en) * | 2009-09-28 | 2012-04-19 | University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| US8575218B2 (en) * | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| US8426368B2 (en) * | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
| JP2012041283A (ja) * | 2010-08-17 | 2012-03-01 | Porien Project Kk | 血管新生抑制剤 |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| SG11201407323WA (en) * | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of local pain |
| WO2015061507A1 (en) * | 2013-10-23 | 2015-04-30 | Chemgenes Corporation | Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces |
| EP3002010A1 (en) * | 2014-09-30 | 2016-04-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling |
| WO2016008603A1 (en) * | 2014-07-16 | 2016-01-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling |
| EP3331894B1 (en) | 2015-08-05 | 2021-02-17 | Metro International Biotech, LLC | Nicotinamide mononucleotide derivatives and their uses |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| WO2017155386A1 (en) * | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for treating brain atrophy |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) * | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| KR20240020716A (ko) | 2021-05-27 | 2024-02-15 | 메트로 인터내셔널 바이오테크 엘엘씨 | 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8319073D0 (en) * | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| AU2789989A (en) * | 1987-10-28 | 1989-05-23 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
| US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| US6090839A (en) * | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
-
2002
- 2002-04-29 RS YUP-765/03A patent/RS51031B/sr unknown
- 2002-04-29 EA EA200301204A patent/EA200301204A1/ru unknown
- 2002-04-29 US US10/476,287 patent/US7560442B2/en not_active Expired - Fee Related
- 2002-04-29 RS RSP-2010/0077A patent/RS20100077A/sr unknown
- 2002-04-29 JP JP2002585457A patent/JP4880190B2/ja not_active Expired - Fee Related
- 2002-04-29 EE EEP201100023A patent/EE201100023A/xx unknown
-
2004
- 2004-09-29 US US10/951,776 patent/US7417034B2/en not_active Expired - Fee Related
- 2004-09-29 US US10/951,764 patent/US7396826B2/en not_active Expired - Fee Related
- 2004-09-29 US US10/951,724 patent/US7915234B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050043269A1 (en) | 2005-02-24 |
| EA200301204A1 (ru) | 2004-04-29 |
| US7560442B2 (en) | 2009-07-14 |
| US7915234B2 (en) | 2011-03-29 |
| US20040121979A1 (en) | 2004-06-24 |
| RS20100077A (sr) | 2010-10-31 |
| JP2004531543A (ja) | 2004-10-14 |
| US20050065110A1 (en) | 2005-03-24 |
| RS51031B (sr) | 2010-10-31 |
| JP4880190B2 (ja) | 2012-02-22 |
| YU76503A (sh) | 2006-05-25 |
| US20050043394A1 (en) | 2005-02-24 |
| US7396826B2 (en) | 2008-07-08 |
| US7417034B2 (en) | 2008-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE201100023A (et) | Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine | |
| ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
| EP1539122A4 (en) | PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS | |
| EE200200486A (et) | Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid | |
| EE200300529A (et) | Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat | |
| FI20022129A7 (fi) | Rasvahappokoostumus, sen valmistus ja käyttö | |
| EE04799B1 (et) | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
| EE05475B1 (et) | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon | |
| ES2571219T8 (es) | Formulación de compuestos de ácido borónico | |
| EE200300587A (et) | Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine | |
| ITMI20001732A0 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti | |
| EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
| DE60206889D1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
| EE05020B1 (et) | Glburiidi ravimkoostis | |
| HUP0402616A3 (en) | Biphenylmethyl-thiazolidinedones, biphenyl-propionic acid derivatives, their use as ppar-gamma activators and pharmaceutical and cosmetic compositions containing them | |
| DE60218175D1 (de) | Stabilisierte orale suspensionsformulierung | |
| EE200300110A (et) | Kaneelhappe asendatud guanidiidid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav ravim | |
| EE04717B1 (et) | Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine | |
| EE200200342A (et) | Asendatud 8-arüülkinoliinid, nende kasutamine, farmatseutiline kompositsioon ja prekursorühend | |
| EE200300488A (et) | Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon | |
| PL361518A1 (pl) | Zastosowanie substancji oraz kompozycja farmaceutyczna | |
| NO20042502L (no) | Farmasoytisk formulering omfattende bicalutamid | |
| EE200200252A (et) | Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks | |
| EE04811B1 (et) | Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim | |
| EE200200637A (et) | Torasemiidi uudne polümorf V, selle valmistamismeetod, kasutamine ja ravimvorm |